Gene therapy biotech Medera looks back to SPAC as way to go public

[cafead]

via You don’t hear about special purpose acquisition company (SPAC) mergers too much these days, but Medera is set to change that as the cardiovascular-disease-focused biotech dusts off this lesser-used pathway to the public markets.

article source